E2F6

Across TCGA pan-cancer cohorts, E2F6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated E2F6 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher E2F6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated E2F6 expression acts as an unfavorable survival marker.

LIHC, COAD, and UCEC are the cancer types where E2F6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.083	0.783	<.001	12	view →
COAD	OS	Median	II,III,IV	0.196	0.788	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

E2F6–LIHC (OS)

Open the LIHC breakdown →